视神经脊髓炎-多发性硬化重叠综合征患者在接受 RTX 治疗后早期复发：多久才能判定治疗失败？
Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?
机构信息
AP-HP, Neurology Department, Pitié-Salpêtrière hospital, 47-83 Boulevard de l'Hôpital, F-75013 Paris, France.
AP-HP, Neurology Department, Pitié-Salpêtrière hospital, 47-83 Boulevard de l'Hôpital, F-75013 Paris, France; Neurology Department, Gui de Chauliac University Hospital, Montpellier, France.
出版信息
Mult Scler Relat Disord. 2018 Feb;20:220-222. doi: 10.1016/j.msard.2018.02.004. Epub 2018 Feb 6.
BACKGROUND
We report a dramatic clinical and radiological worsening within two months after rituximab initiation in a patient with NeuroMyelitis Optica/Multiple Sclerosis (NMO/MS) overlap syndrome.
METHODS
Case study.
RESULTS
A 45-year-old Caucasian woman with NMO/MS overlap syndrome experienced a severe myelitis nine weeks after first rituximab infusion, with extensive new gadolinium-enhanced spinal cord lesions.
CONCLUSION
This case report illustrates the limits of MS and NMO-Spectrum Disorder classification and challenges the criteria of therapeutic failure within the 6 months after rituximab initiation.
背景
我们报告了一例神经髓鞘炎/多发性硬化（NMO/MS）重叠综合征患者在利妥昔单抗治疗开始后两个月内出现的戏剧性临床和影像学恶化。
方法
病例研究。
结果
一名 45 岁的白人女性患有 NMO/MS 重叠综合征，在首次利妥昔单抗输注后 9 周发生严重的脊髓炎，伴有广泛的新的钆增强脊髓病变。
结论
本病例报告说明了 MS 和 NMO 谱系障碍分类的局限性，并对利妥昔单抗治疗开始后 6 个月内治疗失败的标准提出了挑战。
Zotero 插件